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Summary
Throughout  my  PhD  period,  I  experimented  different  approaches  to  a 
complex problem, that is, assessing molecular basis of genetic diseases. In 
the  present  thesis  I  will  show how both  experimental  and  computational 
techniques  can  contribute  to  the  study  of  typical  biochemistry  topics, 
providing  non-conventional  points  of  view  and  advanced  technical  and 
technological supports.
The first part of my PhD was focused on physico-chemical investigation, while 
the  second  part  was  devoted  to  big-data  and  network  analysis.  For  this 
reason my thesis is divided into two chapters.
The former describes a typical bottom-up approach. I applied the physical 
technique of laser light scattering to study the first stages of aggregation of 
configurational variants of the beta-amyloid peptide, recognized to be either 
promoting or preventing the Alzheimer Disease, as compared with the wild 
type peptide.  The variants  correspond to  genetic  mutations  giving rise to 
either familial cases of Alzheimer Disease or protection from the pathology. I 
carried out experiments aimed to assess similarities and differences in the 
kinetics  of  evolution  of  the  aggregated  species  in  very  dilute  solution, 
mimicking the physiological and pathological conditions. The outcome of this 
study is the discovery of a correlation between the molecular structure and 
the  physico-chemical  behavior,  in  this  case  aggregation,  constituting  the 
hallmark of the disease.
The  results  obtained  have  been  published  in  a  peer  reviewed  journal 
(Biophysical Chemistry), with the title: “Pathogenic Aβ A2V versus protective 
Aβ A2T mutation: early stage aggregation and membrane interaction” (2017).
The latter is a top-down approach. I defined the criteria and developed an 
algorithm for searching big databases with respect to: a) the clinical features 
of inherited diseases and b) the proteins that are known to be involved in 
Gamba, A. - Approaches to the molecular basis of genetic diseases                                 2
genetically  determined diseases. I established searching criteria aiming at 
regrouping extracted data according to similarity classes in each database. 
Then, the developed method involves assessing the existence and degree of 
similarity within and between different clusters. As a result of this approach, 
we have discovered a correlation between similarity classes extracted from 
the different databases (the clinical and the biological), thus establishing or 
suggesting the existence of a biological basis for a genetic disease.
The obtained results have been submitted for publication in a peer reviewed 
journal  with  the  title:  “The  Disease  Similarity  Networks:  Correlating  the  
Clinical  and  Biological  Similarity  of  Inherited  Diseases”,  while  a  second 
manuscript is currently under preparation.
Based on different disciplines, and designed with the typical instruments and 
methodologies  of  physics  and  statistics,  both  approaches  give  non-
conventional hints for the understanding of the molecular basis of complex 
genetic diseases.
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Chapter one
1.1 Abstract
The present  study  is  focused  on the  aggregation  of  Amyloid  beta  (Aβ),  a 
peptide  that  plays  an  important  role  in  the  onset  and  progression  of 
Alzheimer disease (AD). This pathology is an increasing form of dementia, 
affecting today large part of the elderly population. The Aβ deposition in the 
brain  starts  with  small  aggregates  and  proceeds  with  formation  of 
extracellular  plaques  and  intracellular  neurofibrillary  tangles,  leading  to 
neuronal  death.  In  our  hypothesis,  early  aggregates  of  Aβ are crucial  for 
understanding the development of AD. Among the different isoforms of Aβ 
peptides that are cleaved from the Amyloid Precursor Protein (APP), we used 
in our analysis the Aβ 1-42, the most toxic and aggregation-prone. The four 
amino acid residues at the N-terminal of Aβ contribute to the formation of a 
stable  β-sheet  secondary  structure.  For  this  reason,  we  take  into 
consideration two mutations found in patients that affect the second position 
of Aβ peptides. These mutations lead to a single amino acid substitution of 
Alanine to Valine (A2V) and Alanine to Threonine (A2T). The carriers of A2T 
mutation surprisingly do not develop AD, whereas A2V mutation causes an 
early-onset and severe AD in homozygous, but not in heterozygous, showing 
(in this last situation) a protective role.
The process of aggregation for Aβ was accurately measured using static and 
dynamic laser  scattering techniques.  This  approach allows to monitor  the 
aggregation from the first steps of process even for small molecules and even 
working at very low concentrations (25 μM). In order to start the experiment 
with  a  monomeric  sample,  we  used  Aβ  synthesized  with  depsipeptides 
method. Moreover, the temperature was maintained constantly low, slowing 
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down the process. Within all the duration of measurements (more than 100 h) 
we calculated the diameter of particles using also the “Non Negative Least 
Squares” (NNLS) algorithm to group aggregates in different populations by 
their size.
As a result, it is immediately possible to observe that the Aβ wild type (WT) 
sample  shows  an  aggregation  poorly  detectable  compared  with  the  two 
mutations, Aβ A2V and Aβ A2T.
The A2V sample surely aggregates better than the other two forms, reflecting 
the  phenotype  observed  in  patients,  who  develop  a  severe  dementia.  As 
shown by measurements, WT and A2V present a very different aggregation 
kinetics  and  characteristic  diameters.  Thus,  we  can  hypothesize  that  the 
protective role, observed in heterozygous A2V patients, is probably due to a 
destructive  interaction  between  WT  and  A2V  peptides  during  their 
aggregation.
People with A2T mutation are healthy but it is not due to the inability of Aβ to 
aggregate, as measured by our technique, and for this reason the causes of 
A2T phenotype need to be better investigated, also with other methods.
All these finds are in accordance with results obtained with parallel studies 
on cell toxicity, enzyme activity and membrane interaction.
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1.2 Introduction
1.2.1 Alzheimer disease overview
Alzheimer disease (AD) is an increasing form of dementia, affecting today 38 
million people worldwide. Among different types of dementias, this pathology 
result to be the most common, especially in elderly people. All the symptoms 
that  characterize  the  Alzheimer  disease  are  related  to  a  progressive  and 
irreversible  deterioration  of  the  higher  cortical  functions  including  mood, 
behavior, and memory. The cause is the degeneration of neurons, a condition 
depicted in the  figure 1  (as also in  figure 5), which clearly illustrates the 
neuronal loss in a brain with advanced AD, compared with normal anatomy. 
Within ten years from the onset of the disease, a cognitive disability occurs, 
such as to determine the complete loss of self-sufficiency in patients.  The 
incidence of AD is a growing function of age as well as its prevalence (which 
doubles every 5 years, starting from 1% around the age of 60), making this 
severe pathology, not only a health problem but also an economic and social 
plague.
Even though some molecular evidences have been emerged, the etiology of 
AD at present remains controversial. Among the proposed hypothesis, one of 
the most widely recognized regards the amyloid cascade (Hardy et al., 2002). 
Following this hypothesis, the fundamental anomaly of AD is the progressive 
deposition of Amyloid beta (Aβ) peptide,  a short protein derived from the 
cleavage  of  Amyloid  Precursor  Protein  (APP),  which  in  turn  is  a 
transmembrane protein with a not completely understand role but with the 
properties of a membrane receptor. The portion of the protein corresponding 
to  Aβ  turns  out  to  be  between  the  extracellular  portion  and  the 
transmembrane domain. The processing of Amyloid Precursor Protein starts 
with a splitting in the extra membrane domain followed by a further intra 
membrane cut by specific enzymes, and is schematically illustrated in  figure 
2. 
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Figure 1: picture of a normal brain (on the left) and a brain in condition of 
advanced Alzheimer disease (on the right)  where a dramatic  reduction of 
neuronal mass is observable.
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Figure 2: a schematic picture of different processing paths (amyloidogenic 
or non amyloidogenic) of APP.
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Depending  on  the  type  of  extracellular  proteolysis  it  may  be  either 
amyloidogenic or not: if the cleavage occurs by the enzyme alfa-secretase, at 
the level of the external cellular surface, followed by a second proteolytic 
event,  by  gamma-secretase,  the  generated   peptides  are  soluble  and  not 
amilodogenic. If APP is processed  by beta-secretase at the level of the N-
terminal  region  and  then  submitted  to  the  second  proteolytic  event,  by 
gamma-secretase,  the  generated  peptides  are  called  Amyloid  beta  (Aβ) 
peptide. The exact location of this cut may vary by giving origin to several 
variants of different length of Aβ peptide. The principal isoforms are two: Aβ 
1-40 (40 amino acid of length) that is the most abundant and Aβ 1-42, that is 
recognized  to  be  the  most  toxic.  The  figure  3 illustrates  the  protein  Aβ 
derived from the APP with its complete amino acid sequence.
The Aβ peptide, once generated, is very prone to aggregating. This process is 
characterized by the formation of oligomers and then protofibrils and fibrils. 
There  are  many  evidences  that  even  small  aggregates  can  be  directly 
neurotoxic. In particular both small and large aggregates tend to stimulate 
an inflammatory response, the consequences of which include alterations of 
the  phosphorylation of  the  tau protein,  inducing  the  generation  of  neuro-
fibrillar clusters.
This cascade appears to offer a number of points at which to interfere with 
the sequence of pathology; however, to date all strategies have faced serious 
hurdles in clinical application, where the tested drugs have been ineffective 
or caused severe adverse events. Thus, there is still an urgent need for safe 
and effective molecules for AD treatment. The amyloid cascade hypothesis is 
depicted in figure 4.
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Figure  3: the  sequence  of  Amyloid  beta  (Aβ).  Derived  from APP,  the  Aβ 
peptides can result with different length, depending by the variable position 
of the gamma-secretase cleavage.
AICD: APP intracellular domain; sAPP: soluble APP.
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Figure 4: schematic representation of progressive steps of the amyloid 
cascade hypothesis.
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1.2.2 Familial Alzheimer disease forms
Most  forms  of  Alzheimer  disease  are  sporadic,  that  is,  they  manifest 
themselves  without  inheritance  among  generations  of  a  family  and  begin 
after 65 years of age. In a minority of cases, however, AD manifests itself at a 
younger  age  (before  60-65  years).  60%  of  these  early-onset  forms  are 
referred to affect different family members, in this case the disease is called 
familial and generally observed in two or more people belonging to the same 
family;  13%  of  them  are  caused  by  the  presence  of  a  genetic  mutation 
present since birth.
These familial forms result to be quite rare in population and characterized 
by premature ages of onset and rapid evolution of the disease, representing 
an important source of information for genetics studies. In a high percentage 
of these forms, especially those characterized by an early onset and a rapid 
evolution, mutations have been identified on the coding genes for Presenilin 
1 (PSI) and Presenilin 2 (PSII) and for the precursor of  Amyloid beta, APP. 
The mutations so far identified are located on chromosomes 1, 14 and 21, for 
PSII, PSI and APP, respectively. Mutations that affect APP cause an abnormal 
production of amyloid beta and its pathological brain buildup in the form of 
“senile plaques” typical of AD patients. PSI and PSII are proteins forming the 
catalytic subunit of the gamma-secretase complex. All these three mutations 
have the same effect, leading to a preferential cleavage of the C-terminus of 
APP that produces Aβ 1-42, a longer form of the normal peptide (1-40). Aβ 1-
42  is  the  neuron-toxic  peptide  that  was  originally  purified  in  the  first 
experiments  from  amyloid  plaques,  in  1984.  These  hereditary  forms  of 
Alzheimer have autosomal dominant transmission and complete penetrance 
(Selkoe et al., 2001).
In  2009 our  research  group  described  a  new APP mutation  (A673V)  that 
causes  early-onset  AD  when  in  homozygosis  (Di  Fede  et  al.,  2009).  The 
missense mutation consists of a C-to-T transition resulting in alanine-to-valine 
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substitution at position 673 of APP, which corresponds to position 2 of Aβ 
peptides (Aβ A2V peptides).  Notably, heterozygous individuals with A2V do 
not develop AD even in advanced age. Effectively, as reported in Di Fede et 
al.  (2009),  five  patients  with  heterozygous  A673V,  performed  well  on  the 
neuropsychological assessments, and the 88 years old aunt of the patients, in 
particular, showed an excellent performance on all the tests, despite she was 
non-educated.
Recently,  another single mutation on the same alanine residue (alanine to 
threonine, A673T) has been reported by Jonsson (Jonsson et al., 2012). This 
mutation,  corresponding  to  the  position  2  of  Aβ peptides  (A2T)  seems to 
protect from the growth of dementias and in particular to hinder the onset of 
AD. The complete mechanism of this protective effect is not yet understood, 
although some studies on different cell models suggest that the presence of 
this mutation reduces the BACE1-mediated processing of APP, then lowering 
the levels of Aβ production (Maloney et al., 2014).
The two punctual  mutations,  A2T and A2V,  and the  wild  type of  Aβ 1-42 




The aim of present work is to study differences in the aggregation process of 
Aβ peptides, in particular, among the wild type peptide and the two mutated 
forms,  A2V and A2T.  In  particular  we focused on the early  stages of  self 
aggregation  process,  by  Static  and  Dynamic  laser  Light  Scattering 
techniques when monomers evolved into oligomers and aggregated soluble 
forms.
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Figure 5: brain magnetic resonance imaging.
Axial T2-weighted images in the early clinical stage of AD  (A), after three 
years  (B),  and after eight years from onset  (C).  Images after eight years 
from onset (D, E). The scans show the progression of the cortico-subcortical 
atrophy and subcortical white matter changes.
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Variation in number of nodes and edges at different thresholds.
Figure L2:
The Clinical Similarity Network (CSN).
Figure L3:
The Biological Similarity Network – Biological Process (BSN-BP).
Figure L4:
The Biological Similarity Network – Cellular Component (BSN-CC).
Figure L5:
The Biological Similarity Network – Molecular Function (BSN-MF).
Figure L6:
The Biological Similarity Network (BSN). The edge thickness is proportional 
to the clinical similarity.
Figure L7:
Cluster analysis of the CSN represented in figure L2.
Figure L8:
Cluster analysis of the BSN represented in figure L6.
Figure L9:
Scatter plot of all PS-PS similarities (A) and a particular of cardiac, 
convulsive and renal diseases (B).
























































































































































































Cluster 3 Cluster 9


































Cluster PS id PS name Cluster PS id PS name
PS604233 Epilepsy, generalized, with febrile seizures plus PS220400 Jervell and Lange-Nielsen syndrome
PS121210 Seizures, familial febrile PS604772 Ventricular tachycardia, catecholaminergic polymorphic
PS121200 Seizures, benign familial neonatal PS609620 Short QT syndrome
PS185800 Proximal symphalangism PS601144 Brugada syndrome
PS186500 Multiple synostoses syndrome PS192500 Long QT syndrome
PS601390 Van Maldergem syndrome PS107970 Arrhythmogenic right ventricular dysplasia
PS268310 Robinow syndrome PS608583 Atrial fibrillation, familial
PS201000 Carpenter syndrome PS113900 Progressive familial heart block
PS248370 Mandibuloacral dysplasia with lipodystrophy PS608567 Sick sinus syndrome
PS608594 Lipodystrophy, congenital generalized PS208000 Generalized arterial calcification of infancy
PS151660 Lipodystrophy, familial partial PS133100 Erythrocytosis, familial
PS256100 Nephronophthisis PS187300 Telangiectasia, hereditary hemorrhagic
PS162000 Hyperuricemic nephropathy, familial juvenile PS168000 Paragangliomas
PS603278 Focal segmental glomerulosclerosis PS191100 Tuberous sclerosis
PS256300 Nephrotic syndrome PS158350 Cowden disease
PS259900 Hyperoxaluria, primary PS131100 Multiple endocrine neoplasia
PS300009 Dent disease PS175100 Familial adenomatous polyposis
PS612286 Nephrolithiasis/osteoporosis, hypophosphatemic PS151623 Li-Fraumeni syndrome
PS134600 Fanconi renotubular syndrome PS120435 Colorectal cancer, hereditary nonpolyposis
PS193100 Hypophosphatemic rickets PS203100 Oculocutaneous albinism
PS145980 Hypocalciuric hypercalcemia PS203300 Hermansky-Pudlak syndrome
PS266600 Inflammatory bowel disease PS133780 Exudative vitreoretinopathy
PS142690 Acne inversa PS136800 Corneal dystrophy, Fuchs endothelial
PS177900 Psoriasis PS122000 Corneal dystrophy, posterior polymorphous
PS114580 Familial candidiasis PS153840 Macular dystrophy, vitelliform
PS308240 Lymphoproliferative syndrome PS136520 Foveal hypoplasia
PS202700 Neutropenia, severe congenital
PS306400 Granulomatous disease, chronic
PS308230 Immunodeficiency with hyper-IgM
PS601495 Agammaglobulinemia
PS607594 Immunodeficiency, common variable











Cluster PS id PS_name Cluster PS id PS_name
1 PS153840 Macular dystrophy, vitelliform 7 PS259900 Hyperoxaluria, primary
8 PS277600 Weill-Marchesani syndrome 7 PS276700 Tyrosinemia
8 PS254090 Ullrich congenital muscular dystrophy 7 PS256520 Neu-Laxova syndrome
8 PS158810 Bethlem myopathy 7 PS210200 Methylcrotonylglycinuria
8 PS228520 Fibrochondrogenesis 7 PS248600 Maple syrup urine disease
8 PS108300 Stickler syndrome 7 PS312170 Pyruvate dehydrogenase complex deficiency
8 PS175780 Porencephaly 7 PS252150 Molybdenum cofactor deficiency
8 PS132400 Epiphyseal dysplasia, multiple 7 PS168000 Paragangliomas
8 PS193900 White sponge nevus 7 PS309801 Linear skin defects with multiple congenital anomalies
6 PS107970 Arrhythmogenic right ventricular dysplasia 7 PS614080 Multiple congenital anomalies-hypotonia-seizures syndrome
6 PS192600 Cardiomyopathy, familial hypertrophic 7 PS239300 Hyperphosphatasia with mental retardation syndrome
6 PS115210 Familial restrictive cardiomyopathy 3 PS211530 Brown-Vialetto-Van Laere syndrome
6 PS308230 Immunodeficiency with hyper-IgM 3 PS249270 Thiamine-responsive dysfunction syndrome
6 PS120100 Familial cold autoinflammatory syndrome 5 PS613280 Hypermanganesemia with dystonia
6 PS241550 Hypoplastic left heart syndrome 5 PS121200 Seizures, benign familial neonatal
6 PS606215 Atrioventricular septal defect 5 PS601764 Seizures, benign familial infantile
6 PS108800 Atrial septal defect 5 PS615040 Familial episodic pain syndrome
6 PS614429 Ventricular septal defect 5 PS211400 Bronchiectasis
6 PS100300 Adams-Oliver syndrome 5 PS601678 Bartter syndrome
6 PS609192 Loeys-Dietz syndrome 5 PS121210 Seizures, familial febrile
6 PS187300 Telangiectasia, hereditary hemorrhagic 5 PS604233 Epilepsy, generalized, with febrile seizures plus
6 PS186500 Multiple synostoses syndrome 5 PS160120 Episodic ataxia
6 PS185800 Proximal symphalangism 5 PS220400 Jervell and Lange-Nielsen syndrome
6 PS266900 Senior-Loken syndrome 5 PS609620 Short QT syndrome
6 PS249000 Meckel syndrome 5 PS601144 Brugada syndrome
4 PS214150 Cerebrooculofacioskeletal syndrome 5 PS608583 Atrial fibrillation, familial
4 PS601675 Trichothiodystrophy 5 PS113900 Progressive familial heart block
4 PS127550 Dyskeratosis congenita 5 PS608567 Sick sinus syndrome
4 PS612199 Cerebroretinal microangiopathy with 
calcifications and cysts 5 PS604772 Ventricular tachycardia, catecholaminergic polymorphic
5 PS192500 Long QT syndrome
5 PS104290 Alternating hemiplegia of childhood
2 PS105250 Amyloidosis, primary localized cutaneous




Disorder types Sim_HPO Sim_GO_max
Cardiac-cardiac 2.49 ± 0.43 3.51 ± 0.43
Cardiac-convulsive 0.12 ± 0.10 2.79 ± 0.48
Convulsive-convulsive 1.65 ± 1.21 2.72 ± 0.49
Renal-renal 1.98 ± 0.52 0.92 ± 0.26
